Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.5%

14 terminated/withdrawn out of 122 trials

Success Rate

84.9%

-1.6% vs industry average

Late-Stage Pipeline

48%

59 trials in Phase 3/4

Results Transparency

32%

25 of 79 completed trials have results

Key Signals

10 recruiting25 with results7 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 4

34(38.6%)

Phase 3

25(28.4%)

N/A

17(19.3%)

Phase 2

7(8.0%)

Phase 1

5(5.7%)

88Total

Phase 4(34)

Phase 3(25)

N/A(17)

Phase 2(7)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (122)

Showing 20 of 122 trials

NCT03855917Phase 4Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

Role: lead

NCT06317051Phase 3Active Not Recruiting

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

Role: lead

NCT07509112Phase 2Not Yet Recruiting

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Role: lead

NCT04014179Not ApplicableCompleted

Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs

Role: lead

NCT03981211Not ApplicableTerminated

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

Role: lead

NCT04914611Recruiting

Real World Assessment of People Living With Chronic Hepatitis B in Australia

Role: lead

NCT03685045Not ApplicableRecruiting

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings

Role: lead

NCT07560046Phase 4Not Yet Recruiting

Combating Related Epidemics in HCV

Role: collaborator

NCT07550595Phase 2Not Yet Recruiting

Oritavancin for Treatment of Serious Cardiac Infections

Role: lead

NCT05042544Recruiting

The Australian HCV Point-of-Care Testing Program

Role: lead

NCT00931463Phase 4Completed

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

Role: lead

NCT07164430Completed

The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory

Role: collaborator

NCT05415267Phase 3Recruiting

Immunosuppression and COVID-19 Boosters

Role: lead

NCT07122219Not ApplicableRecruiting

Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons

Role: collaborator

NCT07145736Phase 4Recruiting

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases

Role: lead

NCT04843761Phase 3Completed

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19